ASCO Lung Cancer Roundtable - NSCLC - New Potential Treatments for MET and RET Positive NSCLC

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.

Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon.

Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic of discussion is new potential treatments for MET and RET positive non small cell lung cancer.

To join the conversation, visit https://cancergrace.org/forum.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

As part of the 2025 Blood Cancer Video Library, where oncologists discuss the most emerging treatment options and information in blood cancer, Dr. Shaji Kumar (Mayo Clinic) discusses optimal strategies for the treatment of newly diagnosed multiple myeloma (MM).

What is the AVO treatment for Chronic Lymphocytic Leukemia (CLL)? Acalabrutinib, Venetoclax, Obinutuzumab for High-Risk Patients

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.